Abstract
Cannabis and its derivatives are being used increasingly by patients with cancer, including patients with glioblastoma multiforme (GBM), the most common and aggressive primary brain malignancy. Despite promising preclinical data suggesting potential anti-cancer effects for cannabinoids in GBM, clinical and safety data are lacking. This editorial will discuss a recent Phase 1b trial of nabiximols oromucosal spray in combination with dose-intense temozolomide in patients with recurrent GBM in the context of other relevant findings in this field.
Publication types
-
Editorial
-
Introductory Journal Article
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Brain Neoplasms / drug therapy*
-
Cannabidiol / administration & dosage*
-
Cannabidiol / pharmacology
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Clinical Trials, Phase I as Topic
-
Dronabinol / administration & dosage*
-
Dronabinol / pharmacology
-
Drug Combinations
-
Glioblastoma / drug therapy*
-
Humans
-
Oral Sprays
-
Temozolomide / administration & dosage*
-
Temozolomide / pharmacology
-
Treatment Outcome
Substances
-
Drug Combinations
-
Oral Sprays
-
Cannabidiol
-
Dronabinol
-
nabiximols
-
Temozolomide